公开(公告)号：EP3212182A1

公开(公告)日：2017-09-06

申请号：EP15787128.6

申请日：2015-10-27

申请人： Pharmacosmos Holding A/s

发明人： RECKE, Christian von der ,  CHRISTENSEN, Tobias S. ,  ANDREASEN, Hans ,  THOMSEN, Lars Lykke

IPC分类号： A61K31/295 ,  A61K31/721 ,  A61P7/06

CPC分类号： A61K31/721 ,  A61K9/0019 ,  A61K31/295 ,  A61K47/10 ,  A61K2300/00

摘要： The present invention relates to an iron carbohydrate complex for use in a method of increasing the blood haemoglobin concentration in a pregnant non-human mammal, wherein the pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, is administered one or more doses of iron carbohydrate complex comprising an amount of elemental iron of 1800 mg or more per dose. The method relates to the further effects of decreasing the rate of stillborn offsprings from a pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, increasing the blood haemoglobin concentration of offspring litters within 3 days from birth and/or weaning, or increasing the litter size in a subsequent parity of a non-human mammal having a blood haemoglobin level of 105 g/L or less.

摘要翻译： 本发明涉及用于提高怀孕的非人类哺乳动物血液血红蛋白浓度的方法中的铁碳水化合物复合物，其中血液中血红蛋白水平为105g / L或更低的怀孕的非人类哺乳动物被施用 一个或多个剂量的铁碳水化合物复合物，其包含每剂量1800mg或更多的元素铁的量。 该方法涉及降低血红蛋白水平为105g / L或更低的怀孕非人类哺乳动物的死胎后代的进一步效果，增加后代产仔3天内血液血红蛋白浓度和/或 断奶或增加具有血红蛋白水平为105g / L或更低的非人哺乳动物的随后胎次的窝产仔数。

公开(公告)号：EP2913054A1

公开(公告)日：2015-09-02

申请号：EP15159781.2

申请日：2015-03-19

申请人： Pharmacosmos Holding A/s

发明人： Thomsen, Lars Lykke ,  Christensen, Tobias S. ,  Andreasen, Hans

IPC分类号： A61K33/26 ,  A61P25/14

CPC分类号： A61K33/26 ,  A61K47/61

摘要： The present invention relates to pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, wherein
the human patient prior to treatment has a magnetic resonance phase imaging of 0.02 radians above the average value of a control group in the substantia nigra, thalamus, putamen, or pallidum.
The invention provides a higher probability for a RLS patient being treated to experience a relief in symptoms.

摘要翻译： 本发明涉及药物组合物，其包含用于治疗或预防人类患者不宁腿综合症（RLS）的方法的铁碳水化合物复合物，其中治疗前的人类患者具有上述0.02弧度的磁共振相成像 黑质，丘脑，壳核或苍白球中对照组的平均值。 本发明为治疗的RLS患者在症状中经历缓解提供了更高的可能性。

公开(公告)号：EP1123103B1

公开(公告)日：2002-10-02

申请号：EP99934521.8

申请日：1999-07-29

申请人： Pharmacosmos Holding A/S

发明人： ANDREASEN, Hans, Berg ,  CHRISTENSEN, Lars

IPC分类号： A61K31/715 ,  A61K31/295 ,  A61K47/48 ,  C08B37/00 ,  A61P3/02

CPC分类号： C08B37/0021 ,  A61K31/721 ,  A61K47/61

摘要： In a process for producing an iron-dextran compound for use in parenteral treatment of iron-deficiency in humans or animals a stable compound of desired relatively low molecular weight is obtained by using first hydrogenation and then oxidation to convert reducing terminal groups on the dextran molecules before reaction with the iron. By varying the ratio of hydrogenated groups to oxygenated groups the average molecular weight of the resulting iron-dextran compound can be varied.